相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CYP2C83 and 4 define CYP2C8 phenotype: An approach with the substrate cinitapride
Diana Maria Campodonico et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Racial Disparity in Drug Disposition in the Digestive Tract
Song Gao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
Pablo Zubiaur et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs
Katherine N. Theken et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
The status of diabetes and its complications in Latin-American population: A review article
Ricardo Correa et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
Miriam Saiz-Rodriguez et al.
BIOMEDICINES (2020)
Postmortem fatal and non-fatal concentrations of amlodipine
J. C. Alvarez et al.
FORENSIC SCIENCE INTERNATIONAL (2020)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Zeruesenay Desta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review andmeta-analysis of randomized controlled trials
Abdul Salam et al.
JOURNAL OF HYPERTENSION (2019)
Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers
Carmen Belmonte et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Efficacy and Tolerability of Telmisartan/Amlodipine plus Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study
Ki-Chul Sung et al.
CLINICAL THERAPEUTICS (2018)
CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
Yun Huang et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2017)
Triple-combination therapy in the treatment of hypertension: a review of the evidence
R. Duesing et al.
JOURNAL OF HUMAN HYPERTENSION (2017)
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1)
Eugene C. Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Amlodipine: The double edged sword
Fatma Rabah et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2017)
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects
Y. Zhou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
R. S. Gammal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system
Carmelo Aguirre et al.
MEDICINA CLINICA (2016)
Racial/Ethnic Differences in Drug Disposition and Response: Review of Recently Approved Drugs
A. Ramamoorthy et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
K. A. Birdwell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients
Chengxian Guo et al.
BIOMEDICAL REPORTS (2015)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update
L. B. Ramsey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
ABCB1 Polymorphism and Gender Affect the Pharmacokinetics of Amlodipine in Chinese Patients with Essential Hypertension: A Population Analysis
Xiao-cong Zuo et al.
DRUG METABOLISM AND PHARMACOKINETICS (2014)
PharmGKB summary: very important pharmacogene information for SLC22A1
Srijib Goswami et al.
PHARMACOGENETICS AND GENOMICS (2014)
Is amlodipine more cardioprotective than other antihypertensive drug classes?
Chang Gyu Park
KOREAN JOURNAL OF INTERNAL MEDICINE (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
CYP3A4 and CYP3A5 Polymorphisms and Blood Pressure Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal Disease
Vibha Bhatnagar et al.
AMERICAN JOURNAL OF NEPHROLOGY (2010)
Sex Differences in Pharmacokinetics and Pharmacodynamics
Offie P. Soldin et al.
CLINICAL PHARMACOKINETICS (2009)
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
Shu-Feng Zhou
CURRENT DRUG METABOLISM (2008)
AmineDB: Large scale docking of amines with CYP2D6 and scoring for druglike properties - towards defining the scope of the chemical defense against foreign amines in humans
A. D. Costache et al.
XENOBIOTICA (2007)
Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
Sarah E. McDowell et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study
F Abad-Santos et al.
PHARMACOLOGICAL RESEARCH (2005)
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
SF Zhou et al.
CLINICAL PHARMACOKINETICS (2005)
Amlodipine besylate-excipients interaction in solid dosage form
A Abdoh et al.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY (2004)
CYP2D6 is involved in O-demethylation of diltiazem -: An in vitro study with transfected human liver
E Molden et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
